

GLAXOSMITHKLINE PLC  
Form 6-K  
July 01, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 01, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

GlaxoSmithKline plc (the 'Company') announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 21 May 2008 it purchased 3,195,000 of its Ordinary shares of 25 pence each

('shares') on 1 July 2008

at a price of 1098.7972

pence per share.

The shares will be cancelled.

Following the cancellation of these shares, the Company holds

474,194,158 of its shares in Treasury, representing 8.97

% of the total voting rights in the Company.

The Company has

5,284,347,049

shares

in issue (excluding Treasury shares). This number

represents the total voting rights in the Company and may be used by

shareholders as the denominator for the calculations by which they can determine

if they are required to notify their interest in, or a change to their interest

in the Company under the Financial Services Authority's Disclosure and  
Transparency Rules.

This announcement does not constitute, or form part of, an offer or any  
solicitation of an offer to purchase or subscribe for securities in any  
jurisdiction and is in conformity with the Financial Services Authority's  
Disclosure and Transparency Rules.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be  
signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 01, 2008

By: VICTORIA WHYTE  
-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc